3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 3
8
Phase 1
4
Phase 4
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma
45
Breast Neoplasms
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
42
Lymphoma, Large B-Cell, Diffuse
41
Lymphoma, Non-Hodgkin
39
Multiple Myeloma
35
Leukemia
34
Melanoma
32
Leukemia, Lymphocytic, Chronic, B-Cell
32
Recurrence
31
Leukemia, Myeloid, Acute
28
Lymphoma, Follicular
27
Lymphoma, B-Cell
25
Ovarian Neoplasms
24
Lymphoma, Mantle-Cell
23
Neoplasm Metastasis
22
Hematologic Neoplasms
19
Pancreatic Neoplasms
18
Myelodysplastic Syndromes
18
Hodgkin Disease
18
Burkitt Lymphoma
16
Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Triple Negative Breast Neoplasms
12
Lymphoma, B-Cell, Marginal Zone
12
Colorectal Neoplasms
12
Stomach Neoplasms
11
Waldenstrom Macroglobulinemia
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Carcinoma, Hepatocellular
9
Interventions
Temozolomide
8
Irinotecan
7
Vincristine
6
Nivolumab
2
temsirolimus
1
talazoparib
1
surufatinib
1
sonidegib
1
silmitasertib
1
regorafenib
1
prexasertib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
liposomal doxorubicin
1
lenvatinib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
irinotecan sucrosofate
1
holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid)
1
ganitumab
1
eribulin
1
efineptakin alfa
1
dostarlimab
1
dinutuximab
1
copanlisib
1
bempegaldesleukin
1
atezolizumab
1
adavosertib
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Rhabdomyosarcoma
×
Cyclophosphamide
×
Clear all
NCT04625907
2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2
Recruiting
1,672 enrolled